⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900335 | 1.00 | — | — | |
| SCHEMBL491480 | 1.00 | — | — | |
| SCHEMBL6913553 | 0.97 | — | — | |
| SCHEMBL6915369 | 0.97 | — | — | |
| SCHEMBL6915268 | 0.97 | — | — | |
| SCHEMBL6916943 | 0.97 | — | — | |
| SCHEMBL6917318 | 0.97 | — | — | |
| SCHEMBL6917129 | 0.97 | — | — | |
| SCHEMBL6916375 | 0.97 | — | — | |
| SCHEMBL8997145 | 0.78 | TDP1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843473-A | Preparation method of levocarnitine impurity | 常州寅盛药业有限公司 | 2024-04-09 | — | — | CN | claimed |
| US-9745341-B2 | Tubulysins and processes for preparing | ENDOCYTE, INC. (US) | 2017-08-29 | — | — | US | claimed |
| US-20160108085-A1 | TUBULYSINS AND PROCESSES FOR PREPARING | ENDOCYTE INC (US) | 2016-04-21 | — | — | US | claimed |
| US-9073884-B2 | Anti-inflammatory and quorum sensing inhibition compounds and methods of making and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-07 | — | — | US | claimed |
| EP-1789029-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| WO-2006024489-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024490-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024491-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| EP-3746436-B1 | FUSED RING COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025092986-A1 | POLYCYCLIC COMPOUND, PREPARATION METHODS AND MEDICINAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-05-08 | — | — | WO | disclosed |
| US-20250059163-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4483881-A2 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| US-20240417408-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-12-19 | — | — | US | disclosed |
| WO-1997036903-A1 | PYRROLOPYRROLONE DERIVATIVES AS INHIBITORS OF NEUTROPHIL ELASTASE | GLAXO GROUP LIMITED (GB) | 1997-10-09 | — | — | WO | disclosed |
| US-5656756-A | PHOTOSENSITIZERS IN PHOTODYNAMIC THERAPY, ANTITUMOR AGENTS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1997-08-12 | — | — | US | disclosed |
| WO-1995029914-A1 | A METHOD OF SYNTHESIZING 5,15-DIARYLBENZOCHLORIN-7-ONE COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1995-11-09 | — | — | WO | disclosed |
| US-4731391-A | Process of making a superabsorbent polyurethane foam | KIMBERLY-CLARK CORPORATION (US) | 1988-03-15 | — | — | US | disclosed |
| US-4725629-A | Process of making an interpenetrating superabsorbent polyurethane foam | KIMBERLY-CLARK CORPORATION (US) | 1988-02-16 | — | — | US | disclosed |
| US-4725628-A | Process of making a crosslinked superabsorbent polyurethane foam | KIMBERLY-CLARK CORPORATION (US) | 1988-02-16 | — | — | US | disclosed |